281 related articles for article (PubMed ID: 32606140)
1. Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer.
Garmpis N; Damaskos C; Garmpi A; Nikolettos K; Dimitroulis D; Diamantis E; Farmaki P; Patsouras A; Voutyritsa E; Syllaios A; Zografos CG; Antoniou EA; Nikolettos N; Kostakis A; Kontzoglou K; Schizas D; Nonni A
In Vivo; 2020; 34(4):1715-1727. PubMed ID: 32606140
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
4. The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC).
Narrandes S; Huang S; Murphy L; Xu W
BMC Cancer; 2018 Jan; 18(1):22. PubMed ID: 29301506
[TBL] [Abstract][Full Text] [Related]
5. Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets.
Wang X; Guda C
Medicine (Baltimore); 2016 Jul; 95(30):e4321. PubMed ID: 27472710
[TBL] [Abstract][Full Text] [Related]
6. Essential amino acid metabolism-related molecular classification in triple-negative breast cancer.
Zhao Y; Pu C; Jiao D; Zhu J; Guo X; Liu Z
Epigenomics; 2021 Aug; 13(16):1247-1268. PubMed ID: 34448400
[TBL] [Abstract][Full Text] [Related]
7. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
[TBL] [Abstract][Full Text] [Related]
8. Integrative analysis of breast cancer profiles in TCGA by TNBC subgrouping reveals novel microRNA-specific clusters, including miR-17-92a, distinguishing basal-like 1 and basal-like 2 TNBC subtypes.
Kalecky K; Modisette R; Pena S; Cho YR; Taube J
BMC Cancer; 2020 Feb; 20(1):141. PubMed ID: 32085745
[TBL] [Abstract][Full Text] [Related]
9. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
Jiang T; Shi W; Wali VB; Pongor LS; Li C; Lau R; Győrffy B; Lifton RP; Symmans WF; Pusztai L; Hatzis C
PLoS Med; 2016 Dec; 13(12):e1002193. PubMed ID: 27959926
[TBL] [Abstract][Full Text] [Related]
10. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
11. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
[TBL] [Abstract][Full Text] [Related]
12. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
13. Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles.
Akhouayri L; Ostano P; Mello-Grand M; Gregnanin I; Crivelli F; Laurora S; Liscia D; Leone F; Santoro A; Mulè A; Guarino D; Maggiore C; Carlino A; Magno S; Scatolini M; Di Leone A; Masetti R; Chiorino G
Hum Genomics; 2022 Dec; 16(1):70. PubMed ID: 36536459
[TBL] [Abstract][Full Text] [Related]
14. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
[TBL] [Abstract][Full Text] [Related]
15. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Reprogramming and Landscape of Transcriptomic Interactions: Impending Therapeutic Interference of Triple-Negative Breast Cancer in Molecular Medicine.
Ray SK; Mukherjee S
Curr Mol Med; 2022; 22(10):835-850. PubMed ID: 34872474
[TBL] [Abstract][Full Text] [Related]
17. Identification of tRNA-derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple-negative breast cancer.
Feng W; Li Y; Chu J; Li J; Zhang Y; Ding X; Fu Z; Li W; Huang X; Yin Y
Cancer Med; 2018 Oct; 7(10):5130-5144. PubMed ID: 30239174
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes.
DiNome ML; Orozco JIJ; Matsuba C; Manughian-Peter AO; Ensenyat-Mendez M; Chang SC; Jalas JR; Salomon MP; Marzese DM
Ann Surg Oncol; 2019 Oct; 26(10):3344-3353. PubMed ID: 31342401
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.
Picornell AC; Echavarria I; Alvarez E; López-Tarruella S; Jerez Y; Hoadley K; Parker JS; Del Monte-Millán M; Ramos-Medina R; Gayarre J; Ocaña I; Cebollero M; Massarrah T; Moreno F; García Saenz JA; Gómez Moreno H; Ballesteros A; Ruiz Borrego M; Perou CM; Martin M
BMC Genomics; 2019 Jun; 20(1):452. PubMed ID: 31159741
[TBL] [Abstract][Full Text] [Related]
20. MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer.
Mathe A; Scott RJ; Avery-Kiejda KA
Int J Mol Sci; 2015 Nov; 16(12):28347-76. PubMed ID: 26633365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
